IPD'S DRUG & CLINICAL REVIEW

THE PREMIER PODCAST FOR DRUG INTELLIGENCE & MANAGEMENT STRATEGY

SAMPLE EPISODES

  • Brand Pricing Terms and Acronyms

    • WAC

    • AWP

    • U&C

    • PBM

  • Brand Pricing Differences Based on Dispensing Method

    • Retail

    • Mail Order

    • Specialty

  • Spread Pricing

  • Generic Pricing Terms and Acronyms

    • Authorized Generic

    • Authorized Biologic

    • MAC

    • Preferred Pharmacy Networks

  • MAC Lists 

  • NDC Codes 

  • Medically Covered Drugs 

  • Methodologies for Medical Drug Reimbursement 

SEE MORE 

Our Executive Clinical Pharmacy Team discusses the basics of generic and brand drug pricing and reimbursement, covering:

DRUG PRICING AND REIMBURSEMENT 101

LIMITED DISTRIBUTION DRUGS 101

Our Executive Clinical Pharmacy talk through the basics of limited distribution drugs and how they affect the marketplace in terms of market access, payer reimbursement, patient care, and drug development.

 

Topics included in this episode:

  • Overview and Basic Definitions of Limited Distribution Drugs and their Networks

  • Pharmacy Motivations for Carrying LDDs

  • Independent Retail Pharmacies 

  • Hospital Perspectives for Providing LDDs

  • Payer Implications for Reimbursing for LDDs

  • Patient Implications for Receiving LDDs

  • Manufacturer Motivations for Developing LDDs

 

SEE MORE

PROVIDER STRATEGIES FOR MAXIMUM REVENUE CAPTURE

Our Executive Clinical Pharmacy team talks through strategies for maximum revenue capture at a time when hospitals are trying to keep up with COVID-19 related admissions, while seeing less revenue coming in from elective procedures and changes to the 340B program are looming.

Topics included in this episode:

  • Revenue Capture Strategies

    • Pharmacy Teams 

    • Revenue Cycle Management Teams 

  • 340B Program Background

    • Pricing and Margin Implications 

    • Recent Changes 

    • Pass-through and Non-pass-through

    • Biosimilars 

    • Drugs with No ASP Pricing

    • Exemptions

    • Litigation 

  • Potential Changes for 2021 

 

SEE MORE

COVID-19 PUBLIC UPDATES

IPD Analytics has released four publicly available podcasts on COVID-19. In each episode, Leslie Fish, R.Ph, Pharm.D. and Julee Oh, Pharm.D. discuss the most recent news on the coronavirus, including:

  • National and Global Status

  • Vaccine Status

  • Current Treatment Options

    • Emergency Use Authorization

    • Clinical Trial Updates

    • Dosing and Administration

    • Warnings and Precautions

    • Availability

  • Manufacturer and Clinical Trial Impacts

  • Stakeholder Impacts

SEE MORE

UNDERSTANDING 505(b)2s

Our Executive Clinical Pharmacy Team discusses 505(b)(2) products and how they compete in the marketplace alongside brand and generic drugs, tackling pricing, market access, and stakeholder implications. 

Specific topics included in this episode:

  • Background on Approval Pathways

  • 505(b)(2) Pathway

  • Interchangeability

  • Potential Barriers to Uptake

  • Payer Implications

  • Provider Implications

  • Manufacturer Motivations for 505(b)(2) Pathway

  • Coding and Reimbursement

  • Manufacturer Pricing and Formulary Access Considerations

  • Development Considerations

  • Prescriber Pushback

SEE MORE

INFECTIOUS DISEASES: HIV AND HEPATITIS C
MANAGEMENT STRATEGY

Our Executive Clinical Pharmacy team discusses the drug pipeline and market landscape for HIV and Hepatitis C, including:

  • HIV:

    • Integrase Strand Transfer Inhibitors (INSTIs) 

    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 

    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

    • Protease Inhibitors

    • Two and Three Tablet Regimens 

    • Single Tablet Regimens 

    • New Guidelines for Recommended Regimens for First-line ART 

    • HIV Pipeline Drugs 

    • 505(b)(2)s 

    • Current Successful Management Strategies

    • Truvada and Descovy for PrEP 

  • Hepatitis C:

    • Recent Key Events 

    • Management Strategies 

 

SEE MORE

IMMUNE GLOBULIN SHORTAGE FALL 2019

Our Executive Clinical Pharmacy team discusses the Immune Globulin (IG) shortage affecting hospitals, infusion centers, specialty pharmacies, and payers across the United States, including:

  • Severity

  • Causes of the shortage

  • Manufacturer comments

  • Treatment options - clinical efficacy and differentiation

  • Patient prioritization tactics

  • Switching and substitution

  • Payer impacts

  • Potential for resolution

SEE MORE

MANUFACTURER LIFE-CYCLE MANAGEMENT STRATEGIES

Our Executive Clinical Pharmacy team explains manufacturer life-cycle management strategies, including specific examples of successes and failures, including:

  • Additional indications

  • New formulations

  • Next generation products

  • Different strengths

  • Bundling

  • Brand over generic strategies

  • Reimbursement incentives and coding strategies

  • Distribution channels

  • Co-pay assistance programs

  • Strategic partnerships

  • Authorized generics

SEE MORE 

UNDERSTANDING AUTHORIZED GENERICS 

Our Executive Clinical Pharmacy Team discusses Authorized Generics (AGs) and their impacts across the marketplace, including:

  • Differences between AGs and traditional generic drugs

  • Manufacturer motivations for launching AGs

  • Examples of current AGs, positioning tactics, and potential launches

  • Impact on price erosion and uptake

  • Forecasting implications

  • Payer considerations for various lines of business

  • And more
     

SEE MORE

AN INSIDE LOOK AT FORMULARY MANAGEMENT AND P&T COMMITTEES

IPD experts take you through the basics of how P&T Committees work to plan their formularies, including:

  • P&T Committee goals, members, and purpose

  • Clinical and financial reviews

  • Formulary tiering

  • Payer formulary planning trends

  • Manufacturer timing and communication strategies for formulary inclusion

SEE MORE

SKINNY LABELS AND OFF-LABEL UTILIZATION

Our clinical pharmacists and and former Federal Circuit Clerks take you through the basics of skinny labels and off-label drug use, including:

  • Definition and motivations behind skinny labels

  • Examples of skinny labels in the market

  • Small molecule drugs vs. biosimilars

  • Payer, provider, manufacturer, retailer, and patient implications

  • Off-label use regulation

 

SEE MORE

Find out how to access all of our podcast episodes!

Asset 211.png
2020 EOY Regional Award Winner Logo-01.p
LINKS
CONTACT & CONNECT

Headquarters:

19950 W Country Club Drive
7th Floor

Aventura, FL 33180

Australia

Brazil

Germany

India

Japan

Mexico

Netherlands

South Korea

Taiwan

info@ipdanalytics.com

+1 (305) 662-8515

  • LinkedIn Social Icon
  • Twitter Social Icon

© 2020 by IPD Analytics | Privacy Policy